Neurological dysfunction in dogs following attenuation of congenital extrahepatic portosystemic shunts

P. L C Tisdall, Geraldine B Hunt, K. R. Youmans, R. Malik

Research output: Contribution to journalArticle

39 Citations (Scopus)

Abstract

Eleven of 89 dogs (12 per cent) developed neurological signs within six days of surgical attenuation of a congenital extrahepatic portosystemic shunt. Neurological signs were not associated with hepatic encephalopathy or hypoglycaemia. Signs varied in severity from non-progressive ataxia (three dogs) to generalised motor seizures (four dogs), progressing to status epilepticus (three dogs). In a further four cases, ataxia and disorientation were treated vigorously with anticonvulsant medication, presumably preventing the development of seizures. Two dogs that developed status epilepticus died or were eventually euthanased. All other animals survived, although some had persistent neurological deficits. Postligation neurological complications were not prevented by gradual shunt attenuation. Prophylactic treatment with phenobarbitone (5 to 10 mg/kg preoperatively, followed by 3 to 5 mg/kg every 12 hours for three weeks) did not significantly reduce the incidence of neurological sequelae (2/31 [6 per cent] dogs with phenobarbitone vs 9/58 [16 per cent] without phenobarbitone; P = 0.2). However, no animal receiving phenobarbitone experienced generalised motor seizures or status epilepticus. In conclusion, these observations suggest that postligation neurological syndrome comprises a spectrum of neurological signs of variable severity. Perioperative treatment with phenobarbitone may not reduce the risk of neurological sequelae, but may reduce their severity.

Original languageEnglish (US)
Pages (from-to)539-546
Number of pages8
JournalJournal of Small Animal Practice
Volume41
Issue number12
StatePublished - 2000
Externally publishedYes

Fingerprint

Surgical Portasystemic Shunt
phenobarbital
Phenobarbital
Dogs
Seizures
Status Epilepticus
dogs
seizures
complications (disease)
Ataxia
anticonvulsants
encephalopathy
Hepatic Encephalopathy
hypoglycemia
Hypoglycemia
Anticonvulsants
drug therapy
animals
incidence
liver

ASJC Scopus subject areas

  • veterinary(all)

Cite this

Neurological dysfunction in dogs following attenuation of congenital extrahepatic portosystemic shunts. / Tisdall, P. L C; Hunt, Geraldine B; Youmans, K. R.; Malik, R.

In: Journal of Small Animal Practice, Vol. 41, No. 12, 2000, p. 539-546.

Research output: Contribution to journalArticle

@article{2de52b95dba24dfeafcdaf637d615fa3,
title = "Neurological dysfunction in dogs following attenuation of congenital extrahepatic portosystemic shunts",
abstract = "Eleven of 89 dogs (12 per cent) developed neurological signs within six days of surgical attenuation of a congenital extrahepatic portosystemic shunt. Neurological signs were not associated with hepatic encephalopathy or hypoglycaemia. Signs varied in severity from non-progressive ataxia (three dogs) to generalised motor seizures (four dogs), progressing to status epilepticus (three dogs). In a further four cases, ataxia and disorientation were treated vigorously with anticonvulsant medication, presumably preventing the development of seizures. Two dogs that developed status epilepticus died or were eventually euthanased. All other animals survived, although some had persistent neurological deficits. Postligation neurological complications were not prevented by gradual shunt attenuation. Prophylactic treatment with phenobarbitone (5 to 10 mg/kg preoperatively, followed by 3 to 5 mg/kg every 12 hours for three weeks) did not significantly reduce the incidence of neurological sequelae (2/31 [6 per cent] dogs with phenobarbitone vs 9/58 [16 per cent] without phenobarbitone; P = 0.2). However, no animal receiving phenobarbitone experienced generalised motor seizures or status epilepticus. In conclusion, these observations suggest that postligation neurological syndrome comprises a spectrum of neurological signs of variable severity. Perioperative treatment with phenobarbitone may not reduce the risk of neurological sequelae, but may reduce their severity.",
author = "Tisdall, {P. L C} and Hunt, {Geraldine B} and Youmans, {K. R.} and R. Malik",
year = "2000",
language = "English (US)",
volume = "41",
pages = "539--546",
journal = "Journal of Small Animal Practice",
issn = "0022-4510",
publisher = "Wiley-Blackwell",
number = "12",

}

TY - JOUR

T1 - Neurological dysfunction in dogs following attenuation of congenital extrahepatic portosystemic shunts

AU - Tisdall, P. L C

AU - Hunt, Geraldine B

AU - Youmans, K. R.

AU - Malik, R.

PY - 2000

Y1 - 2000

N2 - Eleven of 89 dogs (12 per cent) developed neurological signs within six days of surgical attenuation of a congenital extrahepatic portosystemic shunt. Neurological signs were not associated with hepatic encephalopathy or hypoglycaemia. Signs varied in severity from non-progressive ataxia (three dogs) to generalised motor seizures (four dogs), progressing to status epilepticus (three dogs). In a further four cases, ataxia and disorientation were treated vigorously with anticonvulsant medication, presumably preventing the development of seizures. Two dogs that developed status epilepticus died or were eventually euthanased. All other animals survived, although some had persistent neurological deficits. Postligation neurological complications were not prevented by gradual shunt attenuation. Prophylactic treatment with phenobarbitone (5 to 10 mg/kg preoperatively, followed by 3 to 5 mg/kg every 12 hours for three weeks) did not significantly reduce the incidence of neurological sequelae (2/31 [6 per cent] dogs with phenobarbitone vs 9/58 [16 per cent] without phenobarbitone; P = 0.2). However, no animal receiving phenobarbitone experienced generalised motor seizures or status epilepticus. In conclusion, these observations suggest that postligation neurological syndrome comprises a spectrum of neurological signs of variable severity. Perioperative treatment with phenobarbitone may not reduce the risk of neurological sequelae, but may reduce their severity.

AB - Eleven of 89 dogs (12 per cent) developed neurological signs within six days of surgical attenuation of a congenital extrahepatic portosystemic shunt. Neurological signs were not associated with hepatic encephalopathy or hypoglycaemia. Signs varied in severity from non-progressive ataxia (three dogs) to generalised motor seizures (four dogs), progressing to status epilepticus (three dogs). In a further four cases, ataxia and disorientation were treated vigorously with anticonvulsant medication, presumably preventing the development of seizures. Two dogs that developed status epilepticus died or were eventually euthanased. All other animals survived, although some had persistent neurological deficits. Postligation neurological complications were not prevented by gradual shunt attenuation. Prophylactic treatment with phenobarbitone (5 to 10 mg/kg preoperatively, followed by 3 to 5 mg/kg every 12 hours for three weeks) did not significantly reduce the incidence of neurological sequelae (2/31 [6 per cent] dogs with phenobarbitone vs 9/58 [16 per cent] without phenobarbitone; P = 0.2). However, no animal receiving phenobarbitone experienced generalised motor seizures or status epilepticus. In conclusion, these observations suggest that postligation neurological syndrome comprises a spectrum of neurological signs of variable severity. Perioperative treatment with phenobarbitone may not reduce the risk of neurological sequelae, but may reduce their severity.

UR - http://www.scopus.com/inward/record.url?scp=0034567092&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034567092&partnerID=8YFLogxK

M3 - Article

C2 - 11138852

AN - SCOPUS:0034567092

VL - 41

SP - 539

EP - 546

JO - Journal of Small Animal Practice

JF - Journal of Small Animal Practice

SN - 0022-4510

IS - 12

ER -